61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Bio-Techne Corp
Closed
Sector Healthcare
72.58 0.81
Overview
Share price change
24h
Min
71.24
Max
73.84
Income | -7M 34M |
|---|---|
Sales | -17M 290M |
P/E Sector Avg | 76.615 59.362 |
EPS | 0.42 |
Dividend yield | 0.4 |
Profit margin | 11.606 |
EBITDA | 8.9M 81M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +9.65 upside |
Dividend yield Sector Avg | 0.40% 2.35% |
|---|---|
Next Earnings | 5 Feb 2025 |
Next Dividend date | 24 Feb 2025 |
Next Ex Dividend date | 7 Feb 2025 |
Market Cap | 12B |
|---|---|
Previous open | 71.77 |
Previous close | 72.58 |
News Sentiment
By Acuity
50%
50%
149 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Bio-Techne Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bio-Techne Corp Forecast
Price Target
By TipRanks
9.65% upside
12 Months Forecast
Average 79 USD 9.65%
High 79 USD
Low 79 USD
Based on 1 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.
Sentiment
By Acuity
149 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bio-Techne Corp
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
